Sector News

Sanofi signs autoimmune pact with Lead Pharma

February 18, 2015
Life sciences
Sanofi has linked up with Lead Pharma of the Netherlands to develop drugs for a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease.
 
The pact will focus on therapies directed against the nuclear hormone receptors called ROR gamma (t) which drives the production of key pro-inflammatory proteins including interleukin-17A, IL-17F and the receptor for IL-23. Sanofi and Lead say they have a goal of identifying drug candidates and beginning human trials within three-four years.
 
Financial details were not disclosed but the Dutch biotech will receive an upfront payment and is eligible for the usual development, regulatory and commercial milestones, plus royalties. Christian Antoni, head of Sanofi’s immunology and inflammation R&D, said that “anti-ROR gamma (t) therapies represent a ground-breaking opportunity that we are eager and motivated to pursue”.
 
Meantime still no official announcement from Paris about Sanofi’s new chief executive but numerous news sources, notably Bloomberg, say Olivier Brandicourt, head of Bayer’s healthcare business could be crowned in the newt few days. The Frenchman has been one of the front-runners for the post since Chris Viehbacher was sacked in October.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).